Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial  by Young, Lisa R et al.
www.thelancet.com/respiratory   Vol 1   August 2013 445
Articles
Serum VEGF-D concentration as a biomarker of 
lymphangioleiomyomatosis severity and treatment response: 
a prospective analysis of the Multicenter International 
Lymphangioleiomyomatosis Eﬃ  cacy of Sirolimus (MILES) trial
Lisa R Young, Hye-Seung Lee, Yoshikazu Inoue, Joel Moss, Lianne G Singer, Charlie Strange, Koh Nakata, Alan F Barker, Jeﬀ rey T Chapman, 
Mark L Brantly, James M Stocks, Kevin K Brown, Joseph P Lynch 3rd, Hilary J Goldberg, Gregory P Downey, Jeﬀ rey J Swigris, 
Angelo M Taveira-DaSilva, Jeﬀ rey P Krischer, Bruce C Trapnell, Francis X McCormack, for the MILES Trial Group
Summary
 Background VEGF-D is a lymphangiogenic growth factor that has a key role in tumour metastasis. Serum 
VEGF-D concentrations are increased in most patients with lymphangioleiomyomatosis, a rare neoplasm associated 
with mTOR-activating tuberous sclerosis gene mutations, lymphadenopathy, metastatic spread, and pulmonary cyst 
formation. We used data from the Multicenter International Lymphangioleiomyomatosis Eﬃ  cacy of Sirolimus 
(MILES) trial to assess the usefulness of serum VEGF-D concentration as a marker of severity and therapeutic 
response to sirolimus in patients with lymphangioleiomyomatosis. 
Methods In the MILES trial, patients with lymphangioleiomyomatosis who had forced expiratory volume in 1 second 
(FEV₁) of 70% or less of predicted were randomly assigned (1:1) to 12 months masked treatment with sirolimus or placebo. 
Serum VEGF-D concentrations were measured at baseline, 6 months, and 12 months. We used a linear regression model 
to assess associations of baseline VEGF-D concentrations with markers of disease severity, and a linear mixed eﬀ ects 
model to assess the associations of VEGF-D concentrations with between-group diﬀ erences in clinical, physiological, and 
patient-reported outcomes. 
Findings We included 42 patients from the placebo group and 45 from the sirolimus group in our analysis. Baseline 
VEGF-D concentrations in individual patients varied from 0·34 ng/mL to 16·7 ng/mL. Baseline VEGF-D 
concentrations were higher in patients who needed supplemental oxygen than in those who did not need supplemental 
oxygen (1·7 ng/mL [IQR 0·99–3·36] vs 0·84 ng/mL [0·52–1·39]; p<0·0001) and in those who had a bronchodilator 
response than in those who did not (2·01 ng/mL [0·99–2·86] vs 1·00 ng/mL [0·61–2·15]; 0·0273). Median serum 
VEGF-D concentrations were similar at baseline in the sirolimus and placebo groups, and fell from baseline at 6 and 
12 months in the sirolimus group but remained roughly stable in the placebo group. Each one-unit increase in 
baseline log(VEGF-D) was associated with a between-group diﬀ erence in baseline-to-12-month FEV₁ change of 
134 mL (p=0·0007). In the sirolimus group, improvement in baseline-to-12-month FEV₁ occurred in 15 of 23 (65%) 
VEGF-D responders (ie, those in whom baseline-to-12-month VEGF-D concentrations decreased by more than they 
did in any patients in the placebo group) and four of 15 (27%) VEGF-D non-responders (p=0·0448).
Interpretation Serum VEGF-D is a biologically plausible and useful biomarker in lymphangioleiomyomatosis that 
correlates with disease severity and treatment response. Measurement of serum VEGF-D concentrations could 
inform the risk–beneﬁ t analysis of sirolimus therapy in patients with lymphangioleiomyomatosis and reduce the 
numbers of patients needed for clinical trials. 
Funding National Institutes of Health, US Department of Defense.
Introduction
Lymphangioleiomyomatosis is a rare neoplasm that results 
in progressive cystic lung disease and respiratory failure,1 
and aﬀ ects women almost exclusively. Disease can occur in 
two forms: sporadic lymph angio leiomyo matosis or as 
tuberous-sclerosis-complex-associated lymph angio leio-
myo matosis.2 In addition to round, uniform, thin-walled 
cysts distributed randomly throughout the lungs, patients 
with lymph angio leiomyomatosis can have renal angio myo-
lipomas and complications resulting in lymphatic 
inﬁ ltration and obstruction, including lymphadenopathy, 
cystic lymph angioleiomyomas, and chylous ﬂ uid 
collections in the abdomen and chest.3 Lymph angio-
leiomyomatosis is deemed a low-grade metastasising 
neoplasm,1,4 and spread through lymphatic channels and 
recurrence after lung transplantation have been noted.5 
Inappropriate lymphangiogenesis and abundant lymphatic 
channel formation in lymph angio leiomyo matosis lung 
lesions seem to be driven by expression of VEGF-C, 
VEGF-D, and their cognate receptor, VEGFR3.6,7 
VEGF-D is a lymphangiogenic growth factor that has 
a key role in tumour metastasis.8 Serum VEGF-D 
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con centrations are increased in most patients with 
lymph angioleiomyomatosis, but use of these con-
centrations as a marker of disease severity, pro gression, 
and response to treatment has not been established.9–12 
Serum VEGF-D concentrations are normal in women 
with other cystic lung diseases, such as pulmonary 
Langerhan’s cell histiocytosis, emphysema, follicular 
bronchiolitis, lymphoid interstitial pneumonia, and 
Birt-Hogg-Dubé syndrome.10,13 We have previously 
reported that serum concentrations of 0·8 ng/mL 
distinguished lymphangio leiomyomatosis from mimics 
that present as thin-walled cysts visible on high-resolution 
CT (sensitivity 73%, speciﬁ city 100%); at a cutoﬀ  of 
0·6 ng/mL, diagnostic sensitivity of serum VEGF-D was 
84% and speciﬁ city was 98%.10 VEGF-D concentrations 
are increased in women with tuberous-sclerosis-complex-
associated dis ease to an extent greater than that in women 
with sporadic lymphangioleiomyomatosis.10 Furthermore, 
in a cross - sectional study of women with tuberous 
sclerosis complex, a serum con centration of 0·8 ng/mL 
eﬀ ectively discriminated between patients with and 
without cystic changes on chest CT.10 
The mTOR signalling pathway is constitutively 
activated in lymphangioleiomyomatosis because of loss 
of TSC1 or TSC2 function, resulting in dysregulated cell 
growth, motility, and survival.4 Activation of the mTOR 
pathway is blocked by sirolimus, and several studies have 
shown the eﬃ  cacy of mTOR inhibition in the treatment 
of manifestations of tuberous sclerosis complex, 
including angio myolipomas,14–16 subependymal giant cell 
astro cytomas,17 and, most recently, lymphangio leio myo-
matosis.18–20 The Multicenter International Lymph angio-
leiomyomatosis Eﬃ  cacy of Sirolimus (MILES) trial18 was 
an international, randomised, double-blind, placebo-
controlled trial, which showed that sirolimus stabilised 
lung function and was associated with improve ments in 
quality of life and functional performance. In the trial, 
mean serum concentrations of VEGF-D at baseline were 
similar in the placebo and sirolimus groups; con-
centrations fell during 12 months in the sirolimus group 
but remained stable in the placebo group.18 We analysed 
data from the MILES trial to establish the usefulness of 
serum VEGF-D concentration as a marker of severity and 
response to treatment in lymph angio leiomyomatosis. 
Some of our results have been previously reported in 
abstract form.21
Methods
Background and study population
 Our study population comprised participants in the MILES 
trial (who were enrolled at one site in Canada, two sites in 
Japan, and ten sites in the USA) who provided more than 
one serum sample drawn during the trial (ClinicalTrials.
gov number, NCT00414648).18 Brieﬂ y, inclusion criteria for 
the MILES Trial were forced expiratory volume in 1 s 
(FEV₁) of 70% or less of predicted (ie, moderate-to-severe 
lung disease based on FEV₁), a deﬁ nite diagnosis of 
lymph angioleiomyomatosis based on compatible cystic 
changes on chest CT and either biopsy conﬁ rmation or a 
history of angiomyolipomas, tuberous sclerosis complex, 
or chylothorax. Late in the enrolment period, a serum 
VEGF-D concentration of 0·8 ng/mL or greater was added 
as an inclusion criterion. Participants were randomly 
assigned to receive dose-adjusted, double-blinded 
sirolimus or placebo for 1 year. At that point, sirolimus or 
placebo was discontinued and patients were followed up 
for an additional year. Only data from the ﬁ rst year were 
included in our analysis. Pulmonary function testing and 
patient-reported outcomes were gathered serially. The 
MILES trial was approved by the institutional review 
boards at the University of Cincinnati, Cincinnati 
Children’s Hospital Medical Center, and all participating 
sites.  Analysis of VEGF-D as a biomarker was prespeciﬁ ed 
in the MILES trial protocol, and VEGF-D measurements 
were submitted to the data coordinating centre before 
reporting of the primary outcome in the MILES trial.
Procedures
Serum VEGF-D concentrations were measured at 
baseline, 6 months, and 12 months. VEGF-D testing was 
done in a lab that met College of American Pathologists 
and Clinical Laboratory Improvement Amendments 
standards, by technicians masked to treatment 
assignment and clinical data. Reagents included in the 
Quantikine Human VEGF-D Immunoassay (R&D 
Systems, Minneapolis, MN, USA) were used in measure-
ments. Additional methods and performance charac-
teristics of the test are provided in the appendix. 
Pulmonary function testing methodology from the 
MILES trial has been previously reported.18
Statistical analysis
We used a linear regression model to assess the relation 
between baseline VEGF-D concentrations and results 
from pulmonary function tests, 6 min walk tests, and 
patient-reported outcomes. The Wilcoxon rank-sum test 
was used to test for diﬀ erences in baseline serum 
VEGF-D concentrations between subgroups deﬁ ned by 
the historical presence or absence of complicating 
disease features (eg, angiomyolipoma, pneumothorax). 
We used Fisher’s exact test to test for diﬀ erences in 
proportions.
We used linear models to assess whether or not the 
association between serum VEGF-D concentrations and 
pulmonary measures diﬀ ered between treatment groups. 
Although patients were randomly assigned to either 
placebo or sirolimus in the MILES trial, we adjusted for 
age and height in the model to account for diﬀ erences 
between participants at the North American and Japanese 
sites. We examined the interaction between serum 
VEGF-D concentrations at baseline and treatment assign-
ment on pulmonary function tests, 6 min walk tests, or 
patient-reported outcomes. General linear models were 
used to assess absolute changes from baseline to 
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12 months, and linear mixed-eﬀ ects models were used to 
assess changes with time. In the linear mixed-eﬀ ects 
model analysis, we used the Kenward-Roger correction to 
adjust the degree of freedom to improve performance 
when data were missing.22 Log-transformed VEGF-D 
concentrations were used to better ﬁ t the linear models. 
We deemed p values less than 0·05 to be signiﬁ cant. All 
reported p values are two-sided and unadjusted for 
multiple testing. We did all statistical analyses in SAS, 
version 9.2. 
Role of the funding source
The funding sources had no role in study design, data 
analysis, the decision to publish, or writing of this Article. 
Raw data were electronically submitted to the data 
management coordinating centre and accessed by H-SL 
and JPK. The corresponding author had full access to all 
the data and the ﬁ nal responsibility to submit for 
publication.
Results
At baseline, serum samples were available for 87 of the 89 
women with lymphangioleiomyomatosis who parti-
cipated in the MILES trial (ﬁ gure 1). The clinical 
characteristics of the trial population have been 
previously reported.18 23 (26%) participants had a baseline 
FEV₁ of greater than 60% of predicted, 17 (20%) had 
measurements between 51% and 60% of predicted, 
23 (26%) had measurements between 41% and 50% of 
predicted, 15 (17%) had measurements between 31% and 
40% of predicted, and nine (10%) had measurements less 
than or equal to 30% of predicted. Withdrawal during the 
treatment period did not diﬀ er signiﬁ cantly between the 
placebo (seven of 42 patients) and sirolimus (ﬁ ve of 
45 patients) groups (p=0·54).  
Baseline VEGF-D concentrations ranged from 0·34 
ng/mL to 16·7 ng/mL. Age of participants and serum 
concentrations of VEGF-D were not signiﬁ cantly related 
(appendix). Of the 79 patients with sporadic lymph-
angioleiomyomatosis, 54 (68%) had serum VEGF-D 
concentrations greater than or equal to 0·8 ng/mL, 
58 (73%) had concentrations of 0·7 ng/mL or greater, and 
63 (80%) had concentrations of 0·6 ng/mL or greater. 
Baseline concentrations were higher than 0·8 ng/mL in 
seven of the eight patients with tuberous-sclerosis-
complex-associated  lymphangioleiomyomatosis. Median 
baseline serum concentrations of VEGF-D did not diﬀ er 
signiﬁ cantly between patients with tuberous-sclerosis-
complex-associated disease (1·95 ng/mL [IQR 0·96–5·39]) 
and those with the sporadic form of the disease 
(1·27 ng/mL [0·66–2·59]; p=0·27).
Serum VEGF-D concentrations at baseline were 
signiﬁ cantly higher in participants who used 
supplemental oxygen than in those who did not use 
supplemental oxygen (1·7 ng/mL [IQR 0·99–3·36] vs 
0·84 ng/mL [0·52–1·39]; p<0·0001) and in those who 
had a positive bronchodilator response than in those 
who did not (2·01 ng/mL [0·99–2·86] vs 1·00 ng/mL 
[0·61–2·15]; 0·0273; ﬁ gure 2). Patients with a history of 
pneumothorax had signiﬁ cantly lower concentrations 
than did those without such a history (p=0·0015; 
ﬁ gure 2). Baseline concentrations of serum VEGF-D 
were not signiﬁ cantly associated with menopausal 
status or historical presence or absence of angio-
myolipoma (ﬁ gure 2). 
Baseline VEGF-D concentrations were associated with 
markers of airﬂ ow obstruction and hyperinﬂ ation. 
Increased VEGF-D concentrations were positively 
associated with forced vital capacity (FVC), total lung 
capacity, residual volume, functional residual capacity, 
and several patient-reported outcomes, including scores 
on the functional performance inventory and the 
St George’s respiratory questionnaire (table 1), which has 
recently been validated as a long itudinal measure in 
lymphangioleiomyomatosis.23 The associations remained 
signiﬁ cant when we did sensitivity analyses that excluded 
either participants with tuberous-sclerosis-complex-
associated disease or those who were enrolled in the 
MILES trial on the basis of increased VEGF-D 
concentrations (n=12) (data not shown). 
Serum VEGF-D con centrations were similar at baseline 
in the placebo and sirolimus groups.18 VEGF-D con-
centrations remained roughly stable with time in the 
placebo group but fell signiﬁ cantly with time in the 
sirolimus group (p<0·0001; appendix). Between-group 
diﬀ erences in concentration were signiﬁ cant at 6 months 
(p=0·0123) and 12 months (0·0047). Baseline log(VEGF-D) 
correlated negatively (Spearman correlation –0·413; 
p=0·0168) with percentage change in FEV₁ during 
12 months in individual patients in the placebo group and 
positively (0·409; 0·0087) with percentage change in 
42 participants assigned to placebo 45 participants assigned to sirolimus
40 had 6 month VEGF-D data available 37 had 6 month VEGF-D data available
33 had 12 month VEGF-D data available 38 had 12 month VEGF-D data available
89 participants enrolled in MILES trial
2 provided no samples
87 had baseline VEGF-D data
1 withdrew
6 withdrew
5 withdrew
2 no sample 
available
1 no sample 
available
3 no sample 
available
2 no sample 
available
Figure 1: Study population 
MILES=Multicenter International Lymphangioleiomyomatosis Eﬃ  cacy of Sirolimus.
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FEV₁ in those in the sirolimus group (ﬁ gure 3A, 
B; appendix). In the general linear model (which was 
used to compare the absolute diﬀ erence between 
treatment groups), any one-unit increase in baseline 
log(VEGF-D) was associated with a 75 mL increase in 
 FEV₁ from baseline to 12 months in the sirolimus group 
(p=0·0066; ﬁ gure 3C) and a 59 mL decrease in the placebo 
group (0·0007 for between-group comparison; table 2). 
For FVC, any one-unit increase in baseline log(VEGF-D) 
level was associated with a 137 mL increase in FVC from 
baseline to 12 months in the sirolimus group (p=0·0152; 
ﬁ gure 3C) and a 41 mL decrease in the placebo group 
(0·0003 for between-group comparison; table 2). 
From the linear mixed-eﬀ ects models, each one-unit 
increase in baseline log(VEGF-D) was associated with a 
5 mL per month increase in FEV₁ (p=0·0441) and a 14 mL 
per month increase in FVC (0·0034) in the sirolimus 
group, and a 4 mL per month decrease in FEV₁ and 3 mL 
per month decrease in FVC in the placebo group (table 2; 
appendix). The slopes of FEV₁ and FVC responses as a 
function of baseline VEGF-D concentrations were 
signiﬁ cantly diﬀ erent from zero in the treatment group. 
The slopes of lung function responses in the placebo 
group were not signiﬁ cantly diﬀ erent from zero.
FEV₁ at 12 months did not improve in any of the 
22 patients in the placebo group who had baseline 
VEGF-D concentrations of higher than 0·8 ng/mL (the 
cutoﬀ  previously proposed as the conservative diagnostic 
threshold for lymph angio leio myomatosis10) but 
improved in four of 11 (36%) placebo group participants 
with baseline concentrations of less than 0·8 ng/mL 
(appendix). In the sirolimus group, no discrete serum 
VEGF-D threshold was deﬁ nitively associated with 
improvement in FEV₁ but 18 of the 32 (56%) patients in 
the sirolimus group whose baseline VEGF-D con-
centrations were higher than 0·8 ng/mL had 12 month 
FEV₁ measurements that were higher than those at 
baseline (appendix). 
In the placebo group, the maximum change in serum 
VEGF-D concentration from baseline to 12 months was 
42% (mean 0·6 [SD 19·9]), and the change in VEGF-D 
concentration did not correlate with the change in FEV₁ 
during this period (Spearman’s correlation 0·15; 
p=0·42).  We therefore conservatively deﬁ ned VEGF-D 
response in the sirolimus group as a decrease in VEGF-D 
concentration of more than 42% from baseline—ie, the 
maximum change recorded in the placebo group. Of the 
38 patients in the sirolimus group for whom 12 month 
data were available, 23 (61%) had reductions in serum 
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Figure 2: Relation between serum VEGF-D concentrations and disease features at enrolment
Note that the y-axis is broken and that the scale changes. Serum VEGF-D concentrations at baseline were 
signiﬁ cantly higher in participants who used supplemental oxygen than in those who did not use supplemental 
oxygen (p<0·0001) and in those who had a positive bronchodilator response than in those who did not (0·0273). 
Patients with a history of pneumothorax had signiﬁ cantly lower baseline concentrations than did those without 
such a history (0·0015). Baseline concentrations were not signiﬁ cantly associated with menopausal status or 
historical presence or absence of angiomyolipoma.
Log(VEGF-D) p
FEV₁ –0·06 (0·05) 0·24
FVC 0·21 (0·08) 0·0064
DLCO –2·38 (0·52) <0·0001
6 min walk distance –14·47 (13·19) 0·28
FEV1/FVC –0·06 (0·02) 0·0029
Total lung capacity 0·54 (0·14) 0·0002
Functional residual capacity 0·49 (0·12) <0·0001
Residual volume 0·34 (0·11) 0·0031
Functional performance inventory –0·16 (0·06) 0·0144
General wellbeing questionnaire 0·51 (0·61) 0·41
St George’s respiratory questionnaire
Symptoms 2·58 (2·39) 0·28
Activity 5·67 (2·25) 0·0136
Impact 3·96 (2·25) 0·08
Total 4·32 (1·96) 0·0307
36-item short form health survey
Mental –1·94 (1·37) 0·16
Physical –0·91 (1·20) 0·45
European quality of life visual analogue scale
Fatigue 2·77 (3·24) 0·39
Dyspnoea 1·69 (3·14) 0·59
Quality of life –4·55 (2·46) 0·07
Data are parameter estimates for log(VEGF-D) and associated SE from the linear 
regression model with adjustment for height and age. FEV₁=forced expiratory 
volume in 1 s. FVC=forced vital capacity. DLCO=diﬀ using capacity of the lung for 
carbon monoxide.
Table 1: Association between log(VEGF-D) and clinical measurements 
at enrolment
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VEGF-D concentrations from baseline of greater than 
42% at 12 months. Improvement in FEV₁ was noted in 
15 of the 23 (65%) patients with a VEGF-D response and 
four of 15 (27%) without a VEGF-D response in the 
sirolimus group (ﬁ gure 4; p=0·0448). 
Discussion
We used data and samples gathered during the MILES 
trial to show that: baseline serum VEGF-D 
concentration is associated with lymph angio leio myo-
matosis severity; higher baseline serum VEGF-D con-
centrations are associated with improvement in FEV₁ 
and FVC in patients taking sirolimus; and, in patients 
with lymphangioleiomyomatosis who are given 
sirolimus, a decrease in serum VEGF-D concentrations 
with time is associated with improvement in lung 
function (panel). 
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Figure 3: Relation between baseline log(VEGF-D) and 12 month change in 
FEV₁ for individual participants in the placebo (A) and sirolimus (B) groups, 
and expected change from baseline in FEV₁ and FVC (in mL) on the basis of 
each one-log-unit change in baseline log(VEGF-D) (C)
FEV₁=forced expiratory volume in 1 s. FVC=forced vital capacity. 
12 month change per unit increase 
in baseline log(VEGF-D)
Per month change per unit 
increase in baseline 
log(VEGF-D)
Placebo Sirolimus p Placebo Sirolimus p
FEV₁ (mL) –59 (31) 75 (26)* 0·0007 –4 (2) 5 (2)† 0·0090
FVC (mL) –41 (38) 137 (54)† 0·0003 –3 (3) 14 (4)* 0·0015
FEV₁/FVC –0·006 
(0·007)
0·008 
(0·018)
0·40 –0·001 
(0·001)†
–0·000 
(0·001)
0·51
Total lung capacity (mL) 26 (107) 106 (105) 0·42 –11 (8) –0·3 (9) 0·41
Functional residual capacity 
(mL)
–232 (119) –13 (84) 0·36 –15 (8) –7 (7) 0·45
Residual volume (mL) 3 (102) 7 (112) 0·87 –3 (7) –7 (10) 0·78
DLCO (mL/min/mm Hg) –0·840 
(0·494)
0·301 
(0·339)
0·38 0·026 
(0·034)
0·050 
(0·027)
0·52
6 min walk distance (m) –6·038 
(9·265) 
15·27 
(12·96)
0·15 –0·320 
(0·971)
1·228 
(1·019)
0·26
Functional performance 
inventory
–0·056 
(0·044)
0·107 
(0·080)
0·0306 –0·002 
(0·004)
0·008 
(0·006)
0·15
General wellbeing questionnaire –0·898 
(0·916)
–2·172 
(0·965)†
0·36 –0·103 
(0·072)
–0·207 
(0·099)†
0·39
St George’s respiratory questionnaire
Symptoms 6·474 
(2·369)†
–5·589 
(3·762)
0·0056 0·398 
(0·212)
–0·380 
(0·340)
0·0436
Activity 1·900 
(2·015)
–2·577 
(1·990)
0·095 0·108 
(0·167)
–0·313 
(0·185)
0·10
Impact 1·051 
(1·633)
–3·479 
(2·474)
0·0463 –0·019 
(0·170) 
–0·356 
(0·249)
0·21
Total 1·665 
(1·263)
–2·926 
(2·143)
0·0141 0·071 
(0·127)
–0·343 
(0·198)
0·05
36-item short form health survey
Mental 0·442 
(1·340)
1·778 
(1·605)
0·41 0·077 
(0·130)
0·215 
(0·175)
0·53
Physical –1·112 
(0·993)
2·689 
(1·362)
0·0143 –0·072 
(0·098)
0·225 
(0·125)
0·06
European quality of life visual analogue scale
Fatigue –2·884 
(4·168)
–1·227 
(5·063)
0·84 –0·442 
(0·299)
–0·226 
(0·435)
0·71
Dyspnoea 8·291 
(3·833)†
–3·883 
(5·356)
0·057 0·131 
(0·325)
–0·125 
(0·458)
0·63
Quality of life –0·003 
(2·763)
3·996 
(3·356)
0·27 0·084 
(0·230)
0·264 
(0·281)
0·59
A general linear model (adjusted for baseline concentration, age, and height) was the basis for calculation of p values for 
mean 12 month diﬀ erences in lung function and patient-reported outcomes between the placebo and sirolimus groups 
depending on baseline log(VEGF-D). A mixed-eﬀ ects linear model (adjusted for age and height) was used to calculate 
per month p values for no slope diﬀ erence between the placebo and sirolimus groups depending on baseline 
log(VEGF-D). Data are parameter estimates for log(VEGF-D) and associated SE from the general linear and the linear 
mixed eﬀ ects models. Functional performance inventory is scored from 1 to 4, the general wellbeing questionnaire from 
0 to 110, and the European quality of life visual analogue scale from 0 to 100; low score suggests poor health status. 
St George’s respiratory questionnaire is scored from 0 to 100; low score suggests good health status. *p for no eﬀ ect of 
log(VEGF-D) of less than 0·01. †p for no eﬀ ect of log(VEGF-D) less than 0·05.
Table 2: Eﬀ ect of baseline VEGF-D concentrations on selected clinical measurements during the 
Multicenter International Lymphangioleiomyomatosis Eﬃ  cacy of Sirolimus (MILES) trial
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In our analysis, baseline serum VEGF-D concentration 
was a marker of gas exchange abnormalities in lymph-
angioleiomyomatosis (shown by the relation between 
increased VEGF-D concentrations and reduced diﬀ using 
capacity of the lung for carbon monoxide and need for 
supplemental oxygen). Furthermore, higher baseline 
serum VEGF-D concentrations were associated with 
airﬂ ow obstruction (as shown by reduced FEV₁/FVC ratio) 
and bronchodilator responsive ness (deﬁ ned as improve-
ment in FEV₁ or FVC of greater than 12% or 200 mL, or 
both, in patients after salbutamol treatment), which are 
markers of rapid disease progression in lymph angio leio-
myomatosis.24 Patients with higher baseline VEGF-D con-
centrations reported signiﬁ cantly greater impairment in 
day-to-day func tioning and in some quality-of-life domains 
than did those with lower baseline concentrations. 
We noted both similarities and diﬀ erences between our 
ﬁ ndings and those of previous studies9,11,12,25 examining the 
relation between serum VEGF-D concentrations and 
various measures of pulmonary function. Similar to 
Seyama and colleagues,9 we recorded signiﬁ cant 
correlations between baseline VEGF-D concentrations 
and both diﬀ using capacity of the lung for carbon 
monoxide and FEV₁/FVC. However, by contrast with our 
ﬁ ndings, they did not detect an association between 
VEGF-D con centrations and total lung capacity or residual 
volume. In our previous cross-sectional study,10 we did not 
show a relation between VEGF-D concentrations and age, 
FEV₁, or use of supplemental oxygen, whereas signiﬁ cant 
correlations were noted between VEGF-D concentrations 
and FEV₁ and supplemental oxygen use in this analysis of 
the MILES cohort. 
Diﬀ erences between our results and those reported in 
previous studies might be a result of the disparate sample 
sizes and non-contemporaneous nature of data collection 
of previous studies. We chose not to correct for multiple 
comparisons because the analyses were hypo thesis-driven, 
but acknowledge that our approach increases the risk of 
over-interpretation. The association between high VEGF-D 
concentrations and decreased incidence of pneumothorax 
is unexplained. Similarly, the associations between high 
concentrations of VEGF-D and increased FVC, total lung 
capacity, residual volume, and functional residual capacity 
remain incompletely understood. Pulmonary physiological 
impairment in lymph angio leiomyomatosis is complex 
and probably a result of competing forces of obstruction 
(caused by narrowing of airways as a result of smooth 
muscle inﬁ ltration and increased compliance from 
destruction of elastic ﬁ bres) and restriction (related to 
expansion of the interstitial compartment with smooth 
muscle cells). How VEGF-D concentrations are related to 
lymph angio leiomyomatosis cell burden is unknown. 
Incremental increases in baseline VEGF-D con cen-
trations were associated with incremental beneﬁ t from 
treatment in this analysis of a magnitude that compared 
favourably with the estimated minimum clinically 
important FEV₁ diﬀ erence of 100–140 mL for chronic 
obstructive pulmonary disease.26 Collectively, our ﬁ ndings 
suggest that, when weighing the relative merits of 
treatment and watchful waiting in lymphangioleio-
myomatosis, a high VEGF-D concentration portends an 
increased likelihood of therapeutic beneﬁ t in terms of 
FEV₁, FVC, and, perhaps, some aspects of quality of life 
and functional per formance. Additionally, serum VEGF-D 
concentrations might also be useful for stratiﬁ cation of 
patients for trials and reduction of the number of patients 
needed to adequately power studies. The slope of FEV₁ 
response as a function of baseline VEGF-D concentrations 
was diﬀ erent from zero in both statistical models in the 
sirolimus group but not in the placebo group, suggesting 
that incremental increases in baseline VEGF-D con-
centrations were not associated with within-group lung 
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Figure 4: Distribution of baseline-to-12-month change in FEV₁ in participants in the placebo group (A), and relation between VEGF-D response and baseline-to-12-month change in FEV₁ in 
the sirolimus group (B)
Data are shown for all patients who had both VEGF-D concentrations and FEV₁ data at the 12 month study visit (one patient in the placebo group did not have a FEV₁ measurement at 12 months). 
Participants in the sirolimus group were stratified on the basis of VEGF-D response, which was defined as a decrease of greater than 42% in VEGF-D concentrations from baseline to 12 months—ie, the 
maximum change noted in the placebo group. FEV₁=forced expiratory volume in 1 s. *Denotes a participant who did not have a change in FEV₁ at 12 months. †Denotes a VEGF-D nonresponder whose 
FEV₁ decreased by 0·55% at 12 months.
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function decline in the placebo group. Nonetheless, 
patients in the placebo group with VEGF-D concentrations 
of greater than 0·8 ng/mL at baseline had greater declines 
in FEV₁ at 12 months than did those whose baseline 
VEGF-D con centrations were less than 0·8 ng/mL. Taken 
together, these data suggest that baseline VEGF-D con-
centration is associated with disease progression and 
treat ment responses, but the optimum VEGF-D cutoﬀ  for 
treatment decisions will need to be reﬁ ned in future 
studies. 
An early change in VEGF-D concentration after initiation 
of treatment that could be used as a surrogate for 
subsequent lung function response would help to do trials 
more rapidly. VEGF-D responses at 6 months were not 
signiﬁ cantly associated with FEV₁ responses at 12 months 
(data not shown). Because research serum samples were 
taken only every 6 months during the treatment phase of 
the MILES trial, the initial kinetics of the VEGF-D response 
are unknown. We recommend that future studies assess 
early biomarker responses as a potential predictor of 
subsequent clinically meaningful therapeutic responses, 
to identify more rapid surrogate endpoints for trials. 
Although not a central focus of this study, our ﬁ ndings 
conﬁ rm our previously reported VEGF-D diagnostic 
sensitivity and proposed cutoﬀ s, and validate a serum 
concentration of 0·8 ng/mL as a conservative threshold 
for a deﬁ nitive diagnosis of lymph angioleiomyomatosis in 
patients with typical thin-walled cystic change on 
high-resolution CT.10 Because sample handling and assay 
conditions can aﬀ ect serum VEGF-D concentrations, 
normative ranges and standard operating procedures 
should be established in individual laboratories.12,25
Our study had several limitations. The median percent 
predicted FEV1 was 48·5 (SD 13·8) and diﬀ using capacity 
of the lung for carbon monoxide was 43·4 (19) for patients 
with lymphangioleiomyomatosis enrolling in the MILES 
trial,18 consistent with moderately severe disease, although 
FEV₁ was well distributed (from 20–70% of predicted). By 
contrast, the mean FEV₁ reported for the lymph-
angioleiomyomatosis registry from the National Institutes 
of Health was 70% of predicted.27 That a treatment trial 
enrolled patients with more advanced disease than did an 
observational study is perhaps unsurprising; however, 
further studies are needed to establish whether the 
associations and prognostic value of serum VEGF-D 
concentrations would also apply to patients with normal 
lung function or only mild impairment, or in those with 
chylous complications rather than diﬀ use lung disease as 
the main disease manifestation. 
Missing data and withdrawals may have aﬀ ected results, 
although the proportion of missing data was small, 
withdrawals did not diﬀ er substantially between the 
sirolimus and placebo groups during the treatment period, 
and no signiﬁ cant diﬀ erence was noted in VEGF-D 
concentrations between patients who withdrew early and 
12 month trial completers. The MILES trial analysis of 
VEGF-D is confounded by the use of VEGF-D as both a 
trial eligibility criterion and an outcome measure for 12 of 
the 87 (14%) patients, and by the heterogeneity introduced 
by inclusion of patients with tuberous-sclerosis-complex-
associated lymphangioleio myomatosis who might have a 
diﬀ erent disease course from those with sporadic 
lymphangioleiomyomatosis.17 However, patients for whom 
VEGF-D concentration was an eligibility criterion and 
those with tuberous-sclerosis-complex-associated lymph-
angioleiomyomatosis were equally distributed between the 
sirolimus and placebo groups, and sensitivity analyses 
showed that the key analyses remained signiﬁ cant when 
these individuals were excluded. Because of the small 
numbers of patients with tuberous-sclerosis-complex-
associated lymph angio leio myomatosis in the MILES trial, 
future studies are needed to establish whether serum 
VEGF-D con centrations correlate with pulmonary disease 
severity in that population. Furthermore, the reason why 
normal serum VEGF-D concentrations are noted in some 
patients with lymphangioleiomyomatosis remains 
unknown and we are optimistic that future studies will 
might provide insight into disease phenotypes and 
pathogenesis.
Panel: Research in context
Systematic review
In 2009, we searched PubMed, Embase, Scopus, and Web of Science with the terms 
“lymphangioleiomyomatosis and biological markers/biomarkers”, “LAM cells in blood/
urine”, “VEGF-D”, “metalloproteinase”, “osteopontin”, “prognosis/prognostic”, “severity”, 
“predictor/prediction”, “survival analysis”, “score”, “forecasting”, “disease progression”, 
“pneumothoraces”, “chylous eﬀ usions”, “angiomyolipomas”, “sporadic vs TSC-
lymphangioleiomyomatosis”, “postmenopause”, and “cyst size”. When the Multicenter 
International Lymphangioleiomyomatosis Eﬃ  cacy of Sirolimus (MILES) trial closed and was 
reported in 2011, only three original studies9,11,13 of VEGF-D in lymphangioleiomyomatosis 
had been published. Therefore, we concluded that analysis of VEGF-D as a prognostic and 
predictive biomarker of pulmonary disease progression and treatment response was needed 
because no prospective, randomised interventional studies had been done in patients with 
lymphangioleiomyomatosis. On March 1, 2013, we repeated our search strategy in 
PubMmed and identiﬁ ed additional reports of VEGF-D as a diagnostic biomarker and in 
patients with angiomyolipomas associated with tuberous sclerosis, but did not identify any 
other randomised studies in which the relation between VEGF-D concentrations and 
pulmonary treatment response in lymphangioleiomyomatosis was assessed. 
Interpretation
We used the MILES trial data to show that baseline serum VEGF-D is associated with 
lymphangioleiomyomatosis severity. In the MILES trial, high baseline serum VEGF-D 
concentrations were associated with improvement in forced expiratory volume in 1 s (FEV₁) 
and forced vital capacity in patients given sirolimus, whereas a decrease in serum 
concentrations were associated with improvements in lung function. These ﬁ ndings 
suggest that serum VEGF-D concentrations can inform the risk–beneﬁ t analysis of sirolimus 
treatment in patients with lymphangioleiomyomatosis. Whether these results would apply 
to patients who were excluded from the trial (including those with FEV₁ >70% of predicted, 
those with chylous complications impairing lung function, or those who have undergone 
lung transplantation) is unknown. Future studies are needed to establish why serum 
VEGF-D concentrations are normal in some individuals with lymphangioleiomyomatosis, 
and whether VEGF-D-driven lymphangiogenesis is a promising therapeutic target. 
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